Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

Pediatr Infect Dis J. 2002 Feb;21(2):133-8. doi: 10.1097/00006454-200202000-00009.

Abstract

Background: Immunization of young children against cytomegalovirus (CMV) might decrease child-to-child and child-to-adult transmission of CMV and thereby reduce maternal infection during pregnancy. We conducted a Phase I trial in CMV-seronegative toddlers to evaluate the reactogenicity and immunogenicity of a CMV gB vaccine administered with MF59, an oil and water adjuvant.

Methods: Eighteen children between 12 and 35 months of age received either 20 microg of CMV gB/MF59 (n = 15) or a control hepatitis A vaccine (n = 3) at 0, 1 and 6 months. The study was open-label for the first six children and then observer-blinded and randomized. Children were monitored for local and systemic reactions and for the development of antibodies to the envelope protein gB and CMV-neutralizing antibodies.

Results: Adverse reactions were uncommon and mild. Two children were excluded from the immunogenicity analysis because they had serologic evidence of CMV infection. Reciprocal geometric mean neutralizing titers were: 0 preimmunization (n = 18); 90 (range, 53 to 188) after Dose 2 (n = 6); and 638 (range, 210 to 1645) 1 month after Dose 3 (n = 13). The reciprocal geometric mean neutralizing titers of antibody to gB by EIA were: 0 preimmunization (n = 18); 857 (range, 307 to 2073) after Dose 1 (n = 12); 27 457 (range, 9312 to 55,080) after Dose 2 (n = 6); and 98,264 (range, 35,480 to 228,780) 1 month after Dose 3 (n = 5). After Dose 3 antibody responses of toddlers were greater than those of naturally infected adults and were notably higher than among 149 adults given 3 doses of the same vaccine in other trials.

Conclusion: The CMV gB vaccine is well-tolerated and highly immunogenic in toddlers.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adult
  • Antibodies, Viral / analysis*
  • Antibody Formation
  • Child, Preschool
  • Cytomegalovirus Vaccines / administration & dosage
  • Cytomegalovirus Vaccines / adverse effects
  • Cytomegalovirus Vaccines / immunology*
  • Disease Transmission, Infectious / prevention & control
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Infant
  • Male
  • Polysorbates / administration & dosage
  • Pregnancy
  • Pregnancy Complications, Infectious / prevention & control
  • Single-Blind Method
  • Squalene / administration & dosage
  • Viral Envelope Proteins / immunology*

Substances

  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Cytomegalovirus Vaccines
  • MF59 oil emulsion
  • Polysorbates
  • Viral Envelope Proteins
  • glycoprotein B, Simplexvirus
  • Squalene